Myasthenia Gravis Treatment Market Size, Share & Trends Analysis Report By Treatment Type (Thymectomy, Cholinesterase Inhibitors, Rapid Immunotherapies), By End-use (Hospitals, Clinics), By Region and Segment Forecasts, 2023 - 2030

Report
120 Pages
October 2023
Region: Global
Grand View Research
ID: 5899468

The global myasthenia gravis treatment market size is expected to reach USD 4.26 billion by 2030. It is expected to expand at a CAGR of 9.0% from 2023 to 2030. Increasing awareness of rare diseases, emergence of biologics, and growing adoption of immunotherapies & immunosuppressants are driving the myasthenia gravis (MG) treatment market.

Myasthenia gravis (MG) is a rare autoimmune disorder caused by an antibody mediated neuromuscular transmission obstruction that results in skeletal muscle weakness. Some of the disorders associated with the disease include drooping eyelids, double vision, trouble walking, and trouble talking. Patients with MG present with painless muscle weakness that worsens with repeated use and improves with rest.

According to the National Organization for Rare Disorders (NORD), in the U.S. around 14-40 per 100,000 individuals suffer from myasthenia gravis. Reports suggest that the frequency of the disorder is on the rise over the last several decades. This can be attributed to the better identification of patients and the increasing prevalence of autoimmune disorders among general public across the world. Myasthenia gravis occurs more frequently in females than in males, and although symptoms may appear at any age, its onset usually peaks in men in their 50s or 60s and in women during their 20s or 30s.

Medication held the largest market share in the treatment segment and is expected to maintain its market leading position through the forecast period. This is because medications can largely manage the symptoms and dramatically inhibit the immune system. Medications include immunotherapies such as Soliris (eculizumab), corticosteroids, and immunosuppressive drugs such as Prograf (tacrolimus) and Neoral/Sandimmune (cyclosporine). However, high cost of treatment and lack of awareness in the developing & underdeveloped countries are expected to inhibit the market growth.

Myasthenia Gravis Treatment Market Growth & Trends
-Medications can dramatically inhibit the immune system and largely manage the associated symptoms. Medications include immunotherapies such as Soliris (eculizumab), corticosteroids, and immunosuppressive drugs such as Prograf (tacrolimus) and Neoral/Sandimmune (cyclosporine).
-The monoclonal antibodies segment held the largest market share of over 60% in 2022 and is expected to maintain its leading position through the forecast period, owing to the high precision in treating myasthenia gravis and better efficacy.
-Based on end use, the market has been segmented into hospitals, clinics, and others. The hospital segment held the largest market share of around 55% in 2022 and is expected to grow at a lucrative CAGR of 9.0% over the forecast period.
-In 2022, North America had the largest market share of over 50% and is projected to lead the market throughout the forecast period.
-Asia Pacific is anticipated to grow at a lucrative CAGR through the forecast period due to the increase in revenue generation from medications such as immunosuppressants and monoclonal antibodies in this region.

This product will be delivered within 1-3 business days.

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.1.1. Treatment Type
1.1.2. End use
1.1.3. Regional scope
1.1.4. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Treatment outlook
2.2.2. End use outlook
2.2.3. Regional outlook
2.3. Competitive Insights

Chapter 3. Myasthenia Gravis Treatment Market Variables, Trends & Scope

3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Myasthenia Gravis Treatment Market Analysis Tools
3.4.1. Industry Analysis - Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape

Chapter 4. Myasthenia Gravis Treatment: Treatment Type Estimates & Trend Analysis

4.1. Myasthenia Gravis Treatment Market: Key Takeaways
4.2. Myasthenia Gravis Treatment Market: Movement & Market Share Analysis, 2022 & 2030
4.3. Cholinesterase Inhibitors
4.3.1. Cholinesterase inhibitors market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Chronic Immunomodulators
4.4.1. Chronic immunomodulators market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. Monoclonal Antibodies
4.5.1. Monoclonal antibodies market estimates and forecasts, 2018 to 2030 (USD Million)
4.6. Rapid Immunotherapies
4.6.1. Rapid immunotherapies market estimates and forecasts, 2018 to 2030 (USD Million)
4.7. Thymectomy
4.7.1. Thymectomy market estimates and forecasts, 2018 to 2030 (USD Million)
4.8. Others
4.8.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Myasthenia Gravis Treatment: End Use Estimates & Trend Analysis

5.1. Myasthenia Gravis Treatment Market: Key Takeaways
5.2. Myasthenia Gravis Treatment Market: Movement & Market Share Analysis, 2022 & 2030
5.3. Hospitals
5.3.1. Hospitals market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. Clinics
5.4.1. Clinics market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Others
5.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Myasthenia Gravis Treatment Market: Regional Estimates & Trend Analysis

6.1. Regional Outlook
6.2. Myasthenia Gravis Treatment Market by Region: Key Marketplace Takeaway
6.3. North America
6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.3.2. U.S.
6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.3.3. Canada
6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4. Europe
6.4.1. UK
6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.2. Germany
6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.3. France
6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.4. Italy
6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.5. Spain
6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.6. Sweden
6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.7. Norway
6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.8. Denmark
6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5. Asia Pacific
6.5.1. Japan
6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.2. China
6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.3. India
6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.4. Australia
6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.5. Thailand
6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.6. South Korea
6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.6. Latin America
6.6.1. Brazil
6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.6.2. Mexico
6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.6.3. Argentina
6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7. MEA
6.7.1. Saudi Arabia
6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7.2. South Africa
6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7.3. UAE
6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7.4. Kuwait
6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Market Participant Categorization
7.2.1. Alexion Pharmaceutical Inc.
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Product benchmarking
7.2.1.4. Strategic initiatives
7.2.2. Grifols SA
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Product benchmarking
7.2.2.4. Strategic initiatives
7.2.3. Avadel Pharmaceuticals, Plc.
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. Novartis
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. Pfizer, Inc.
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. AbbVie Inc.
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. F.Hoffmann-La Roche AG
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives
7.2.8. GlaxoSmithKline Plc.
7.2.8.1. Company overview
7.2.8.2. Financial performance
7.2.8.3. Product benchmarking
7.2.8.4. Strategic initiatives
7.2.9. Bausch Health Companies Inc.
7.2.9.1. Company overview
7.2.9.2. Financial performance
7.2.9.3. Product benchmarking
7.2.9.4. Strategic initiatives
7.2.10. Shire plc
7.2.10.1. Company overview
7.2.10.2. Financial performance
7.2.10.3. Product benchmarking
7.2.10.4. Strategic initiatives

List of Tables

Table 1 List of Abbreviation
Table 2 North America myasthenia gravis treatment market, by treatment type, 2018-2030 (USD Million)
Table 3 North America myasthenia gravis treatment market, by end use, 2018-2030 (USD Million)
Table 4 North America myasthenia gravis treatment market, by region, 2018-2030 (USD Million)
Table 5 U.S. myasthenia gravis treatment market, by treatment type, 2018-2030 (USD Million)
Table 6 U.S. myasthenia gravis treatment market, by end use, 2018-2030 (USD Million)
Table 7 Canada myasthenia gravis treatment market, by treatment type, 2018-2030 (USD Million)
Table 8 Canada myasthenia gravis treatment market, by end use, 2018-2030 (USD Million)
Table 9 Europe myasthenia gravis treatment market, by treatment type, 2018-2030 (USD Million)
Table 10 Europe myasthenia gravis treatment market, by end use, 2018-2030 (USD Million)
Table 11 Europe myasthenia gravis treatment market, by region, 2018-2030 (USD Million)
Table 12 Germany myasthenia gravis treatment market, by treatment type, 2018-2030 (USD Million)
Table 13 Germany myasthenia gravis treatment market, by end use, 2018-2030 (USD Million)
Table 14 UK myasthenia gravis treatment market, by treatment type, 2018-2030 (USD Million)
Table 15 UK myasthenia gravis treatment market, by end use, 2018-2030 (USD Million)
Table 16 France myasthenia gravis treatment market, by treatment type, 2018-2030 (USD Million)
Table 17 France myasthenia gravis treatment market, by end use, 2018-2030 (USD Million)
Table 18 Italy myasthenia gravis treatment market, by treatment type, 2018-2030 (USD Million)
Table 19 Italy myasthenia gravis treatment market, by end use, 2018-2030 (USD Million)
Table 20 Spain myasthenia gravis treatment market, by treatment type, 2018-2030 (USD Million)
Table 21 Spain myasthenia gravis treatment market, by end use, 2018-2030 (USD Million)
Table 22 Sweden myasthenia gravis treatment market, by treatment type, 2018-2030 (USD Million)
Table 23 Sweden myasthenia gravis treatment market, by end use, 2018-2030 (USD Million)
Table 24 Norway myasthenia gravis treatment market, by treatment type, 2018-2030 (USD Million)
Table 25 Norway myasthenia gravis treatment market, by end use, 2018-2030 (USD Million)
Table 26 Denmark myasthenia gravis treatment market, by treatment type, 2018-2030 (USD Million)
Table 27 Denmark myasthenia gravis treatment market, by end use, 2018-2030 (USD Million)
Table 28 Asia Pacific myasthenia gravis treatment market, by treatment type, 2018-2030 (USD Million)
Table 29 Asia Pacific myasthenia gravis treatment market, by end use, 2018-2030 (USD Million)
Table 30 Asia Pacific myasthenia gravis treatment market, by region, 2018-2030 (USD Million)
Table 31 China myasthenia gravis treatment market, by treatment type, 2018-2030 (USD Million)
Table 32 China myasthenia gravis treatment market, by end use, 2018-2030 (USD Million)
Table 33 Japan myasthenia gravis treatment market, by treatment type, 2018-2030 (USD Million)
Table 34 Japan myasthenia gravis treatment market, by end use, 2018-2030 (USD Million)
Table 35 India myasthenia gravis treatment market, by treatment type, 2018-2030 (USD Million)
Table 36 India myasthenia gravis treatment market, by end use, 2018-2030 (USD Million)
Table 37 Australia myasthenia gravis treatment market, by treatment type, 2018-2030 (USD Million)
Table 38 Australia myasthenia gravis treatment market, by end use, 2018-2030 (USD Million)
Table 39 Thailand myasthenia gravis treatment market, by treatment type, 2018-2030 (USD Million)
Table 40 Thailand myasthenia gravis treatment market, by end use, 2018-2030 (USD Million)
Table 41 South Korea myasthenia gravis treatment market, by treatment type, 2018-2030 (USD Million)
Table 42 South Korea myasthenia gravis treatment market, by end use, 2018-2030 (USD Million)
Table 43 Latin America myasthenia gravis treatment market, by treatment type, 2018-2030 (USD Million)
Table 44 Latin America myasthenia gravis treatment market, by end use, 2018-2030 (USD Million)
Table 45 Latin America myasthenia gravis treatment market, by region, 2018-2030 (USD Million)
Table 46 Brazil myasthenia gravis treatment market, by treatment type, 2018-2030 (USD Million)
Table 47 Brazil myasthenia gravis treatment market, by end use, 2018-2030 (USD Million)
Table 48 Mexico myasthenia gravis treatment market, by treatment, type 2018-2030 (USD Million)
Table 49 Mexico myasthenia gravis treatment market, by end use, 2018-2030 (USD Million)
Table 50 Argentina myasthenia gravis treatment market, by treatment type, 2018-2030 (USD Million)
Table 51 Argentina myasthenia gravis treatment market, by end use, 2018-2030 (USD Million)
Table 52 Middle East and Africa myasthenia gravis treatment market, by treatment type, 2018-2030 (USD Million)
Table 53 Middle East and Africa myasthenia gravis treatment market, by end use, 2018-2030 (USD Million)
Table 54 Middle East and Africa myasthenia gravis treatment market, by region, 2018-2030 (USD Million)
Table 55 South Africa myasthenia gravis treatment market, by treatment type, 2018-2030 (USD Million)
Table 56 South Africa myasthenia gravis treatment market, by end use, 2018-2030 (USD Million)
Table 57 Saudi Arabia myasthenia gravis treatment market, by treatment type, 2018-2030 (USD Million)
Table 58 Saudi Arabia myasthenia gravis treatment market, by end use, 2018-2030 (USD Million)
Table 59 UAE myasthenia gravis treatment market, by treatment type, 2018-2030 (USD Million)
Table 60 UAE myasthenia gravis treatment market, by end use, 2018-2030 (USD Million)
Table 61 Kuwait myasthenia gravis treatment market, by treatment type, 2018-2030 (USD Million)
Table 62 Kuwait myasthenia gravis treatment market, by end use, 2018-2030 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Myasthenia gravis treatment: Market outlook
Fig. 9 Myasthenia gravis treatment: Competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Industry value chain analysis
Fig. 14 Myasthenia gravis treatment market driver impact
Fig. 15 Myasthenia gravis treatment market restraint impact
Fig. 16 Myasthenia gravis treatment market strategic initiatives analysis
Fig. 17 Myasthenia gravis treatment market: Treatment type movement analysis
Fig. 18 Myasthenia gravis treatment market: Treatment type outlook and key takeaways
Fig. 19 Cholinesterase inhibitors market estimates and forecasts, 2018-2030 (USD Million)
Fig. 20 Chronic immunomodulators market estimates and forecasts, 2018-2030 (USD Million)
Fig. 21 Monoclonal antibodies market estimates and forecasts, 2018-2030 (USD Million)
Fig. 22 Rapid immunotherapies market estimates and forecasts, 2018-2030 (USD Million)
Fig. 23 Thymectomy market estimates and forecasts, 2018-2030 (USD Million)
Fig. 24 Others market estimates and forecasts, 2018-2030 (USD Million)
Fig. 25 Myasthenia gravis treatment market: End use movement analysis
Fig. 26 Myasthenia gravis treatment market: End use outlook and key takeaways
Fig. 27 Hospitals market estimates and forecasts, 2018-2030 (USD Million)
Fig. 28 Clinics market estimates and forecasts, 2018-2030 (USD Million)
Fig. 29 Others market estimates and forecasts, 2018-2030 (USD Million)
Fig. 30 Global myasthenia gravis treatment market: Regional movement analysis
Fig. 31 Global myasthenia gravis treatment market: Regional outlook and key takeaways
Fig. 32 North America market estimates and forecasts, 2018-2030 (USD Million)
Fig. 33 U.S. market estimates and forecasts, 2018-2030 (USD Million)
Fig. 34 Canada market estimates and forecasts, 2018-2030 (USD Million)
Fig. 35 Europe market estimates and forecasts, 2018-2030 (USD Million)
Fig. 36 UK market estimates and forecasts, 2018-2030 (USD Million)
Fig. 37 Germany market estimates and forecasts, 2018-2030 (USD Million)
Fig. 38 France market estimates and forecasts, 2018-2030 (USD Million)
Fig. 39 Italy market estimates and forecasts, 2018-2030 (USD Million)
Fig. 40 Spain market estimates and forecasts, 2018-2030 (USD Million)
Fig. 41 Sweden market estimates and forecasts, 2018-2030 (USD Million)
Fig. 42 Norway market estimates and forecasts, 2018-2030 (USD Million)
Fig. 43 Denmark market estimates and forecasts, 2018-2030 (USD Million)
Fig. 44 Asia Pacific market estimates and forecasts, 2018-2030 (USD Million)
Fig. 45 Japan market estimates and forecasts, 2018-2030 (USD Million)
Fig. 46 China market estimates and forecasts, 2018-2030 (USD Million)
Fig. 47 India market estimates and forecasts, 2018-2030 (USD Million)
Fig. 48 Australia market estimates and forecasts, 2018-2030 (USD Million)
Fig. 49 Thailand market estimates and forecasts, 2018-2030 (USD Million)
Fig. 50 South Korea market estimates and forecasts, 2018-2030 (USD Million)
Fig. 51 Latin America market estimates and forecasts, 2018-2030 (USD Million)
Fig. 52 Brazil market estimates and forecasts, 2018-2030 (USD Million)
Fig. 53 Mexico market estimates and forecasts, 2018-2030 (USD Million)
Fig. 54 Argentina market estimates and forecasts, 2018-2030 (USD Million)
Fig. 55 Middle East and Africa. market estimates and forecasts, 2018-2030 (USD Million)
Fig. 56 Saudi Arabia market estimates and forecasts, 2018-2030 (USD Million)
Fig. 57 South Africa market estimates and forecasts, 2018-2030 (USD Million)
Fig. 58 UAE market estimates and forecasts, 2018-2030 (USD Million)
Fig. 59 Kuwait market estimates and forecasts, 2018-2030 (USD Million)

Companies Mentioned

Alexion Pharmaceutical Inc.
Grifols SA
Avadel Pharmaceuticals, Plc.
Novartis
Pfizer, Inc.
AbbVie Inc.
F.Hoffmann-La Roche AG
GlaxoSmithKline Plc.
Bausch Health Companies Inc.
Shire plc

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	120
Published	October 2023
Forecast Period	2022 - 2030
Estimated Market Value ( USD ) in 2022	$ 2.01 Billion
Forecasted Market Value ( USD ) by 2030	$ 4.26 Billion
Compound Annual Growth Rate	9.0%
Regions Covered	Global
No. of Companies Mentioned	10

PURCHASE OPTIONS

Single User License PDF

1 - 5 User License PDF

Enterprise License PDF

need a quote ?

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€5752EUR$5,950USD£4,941GBP
1 - 5 USER LICENSE PDF	The product is a PDF.	This is a 1-5 user license, allowing up to five users have access to the product.	€6719EUR$6,950USD£5,771GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€8653EUR$8,950USD£7,432GBP

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Myasthenia Gravis Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2023 To 2031

Global Myasthenia Gravis Treatment Market by Type (Medication, Surgery), End-User (Clinics, Hospitals) - Forecast 2024-2030

Myasthenia Gravis Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030

Myasthenia Gravis Drugs - Global Strategic Business Report

Myasthenia Gravis Treatment - Global Strategic Business Report